WHOLE SHINE MEDICAL(002622)

Search documents
皓宸医疗(002622) - 2021 Q3 - 季度财报
2021-10-29 16:00
Financial Performance - The company's operating revenue for Q3 2021 was ¥27,295,409.54, a decrease of 4.51% compared to the same period last year, while year-to-date revenue increased by 31.22% to ¥76,394,047.11[6] - The net profit attributable to shareholders for Q3 2021 was a loss of ¥8,070,454.04, representing a decline of 271.41% year-on-year, while year-to-date net profit increased by 104.30% to ¥1,190,683.07[6] - Basic and diluted earnings per share for Q3 2021 were both -¥0.0096, a decrease of 271.41% compared to the same period last year, while year-to-date earnings per share increased by 104.24% to ¥0.0014[6] - Total operating revenue for Q3 2021 was CNY 76,394,047.11, an increase of 31.1% compared to CNY 58,217,553.26 in the same period last year[29] - Net profit for Q3 2021 was CNY 1,190,683.07, a significant recovery from a net loss of CNY 27,711,292.48 in Q3 2020[30] - Basic and diluted earnings per share for the quarter were both ¥0.0014, a recovery from a loss of ¥0.0330 per share in the previous year[31] - The total comprehensive income attributable to the parent company was -¥20,094,935.58, compared to -¥18,765,711.38 in the same period last year, reflecting a decline of about 7.1%[31] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥1,375,052,149.42, an increase of 2.57% from the end of the previous year[7] - The company's equity attributable to shareholders decreased by 2.31% to ¥850,968,343.79 compared to the end of the previous year[7] - The company's total assets reached CNY 1,375,052,149.42, compared to CNY 1,340,539,193.47 at the end of the previous quarter[27] - Current liabilities increased to CNY 434,561,291.61 from CNY 379,614,972.28 in the previous quarter[26] - The total equity attributable to shareholders was CNY 850,968,343.79, down from CNY 871,063,279.37 in the previous quarter[27] - The total liabilities stood at approximately ¥469.48 million, indicating a debt-to-equity ratio of about 54%[39] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥9,907,822.34, a decrease of 69.14% compared to the previous year[6] - The net cash flow from operating activities was ¥9,907,822.34, down from ¥32,107,785.48 in the previous year, indicating a decline of about 69.1%[34] - The cash inflow from operating activities totaled ¥81,268,842.35, down from ¥107,364,752.48 in the previous year, a decrease of approximately 24.3%[34] - The cash outflow from operating activities was ¥71,361,020.01, slightly lower than ¥75,256,967.00 in the previous year, indicating a decrease of about 5.3%[34] - The total cash and cash equivalents at the end of the period increased to ¥223,411,061.97, compared to ¥101,130,216.04 at the end of the previous year, representing a growth of approximately 120.5%[35] - The net cash flow from investment activities was ¥75,000,000.00, significantly higher than ¥30,055,072.05 in the previous year, marking an increase of about 149.2%[34] - The net cash flow from financing activities was -¥52,958,214.08, worsening from -¥32,365,343.73 in the same period last year, indicating a decline of approximately 63.8%[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 61,273[17] - The largest shareholder, Guangzhou Huiyin Rifeng Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[17] Strategic Initiatives - The company plans to acquire 51% of Guangzhou Delun Medical Investment Co., Ltd. for a total cash consideration of 246 million RMB, with 141 million RMB for 30% from one party and 105 million RMB for 21% from another[19] - The assessed value of Delun Medical's total equity as of May 31, 2021, is approximately 569.62 million RMB[20] - The company aims to enhance its profitability by integrating high-quality assets, particularly through the acquisition of Delun Medical, which focuses on oral healthcare services[21] - The company is actively expanding into the oral healthcare service industry, which has significant market potential[21] - The upcoming shareholder meeting on November 11, 2021, will review the related matters of the asset acquisition[22] - The company has identified the need to improve its core business profitability to support sustainable development[21] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] Research and Development - Research and development expenses for Q3 2021 were CNY 6,098,463.04, compared to CNY 5,597,304.27 in Q3 2020, indicating a focus on innovation[30] Other Financial Metrics - Investment income decreased by ¥19,601,300, or 45.13%, due to reduced net profit from the company's associate, Fushun Bank[12] - The company experienced a 97.76% decrease in credit impairment losses compared to the same period last year, reflecting a reduction in provisions made in the previous year[13] - The company reported an investment income of CNY 23,828,877.58, a decrease from CNY 43,430,179.18 in the same period last year[30] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[41]
皓宸医疗(002622) - 2021 Q2 - 季度财报
2021-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was ¥49,098,637.57, representing a 65.69% increase compared to ¥29,632,396.01 in the same period last year[19]. - The net profit attributable to shareholders was ¥9,261,137.11, a significant turnaround from a loss of ¥32,419,460.31 in the previous year, marking a 128.57% improvement[19]. - The net profit after deducting non-recurring gains and losses was ¥8,346,837.84, compared to a loss of ¥33,835,256.29 in the same period last year, reflecting a 124.67% increase[19]. - The basic earnings per share increased to ¥0.0110 from a loss of ¥0.0386, showing a 128.50% improvement[19]. - The total operating revenue for the first half of 2021 reached ¥49,098,637.57, a significant increase of 65.6% compared to ¥29,632,396.01 in the same period of 2020[136]. - The company reported a net profit of ¥9,261,137.11 for the first half of 2021, a turnaround from a net loss of ¥32,419,460.31 in the first half of 2020[138]. - The total comprehensive income for the first half of 2021 was ¥20,166,731.97, a significant recovery from a loss of ¥28,851,587.81 in the previous year[139]. - The company reported a net loss of approximately RMB 8.21 million for the first half of 2021, indicating a significant decline in profitability[163]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,401,582,549.01, up 4.55% from ¥1,340,539,193.47 at the end of the previous year[19]. - The total liabilities increased to CNY 510,007,955.13 from CNY 469,476,440.14, reflecting a rise of about 8.6%[130]. - The company's total equity at the end of the reporting period was 1,246,920.90 yuan, down from 1,284,000.00 yuan at the beginning of the period, indicating a reduction of approximately 2.9%[156]. - The total liabilities at the end of the current period were not specified, indicating a need for further financial clarity[160]. Cash Flow - The net cash flow from operating activities was ¥5,461,770.60, a decrease of 53.63% compared to ¥11,779,170.25 in the same period last year[19]. - The cash flow from operating activities was ¥46,512,302.47, compared to ¥54,557,946.14 in the first half of 2020, indicating a decrease in cash inflow from operations[145]. - The total cash inflow from investment activities was ¥45,000,000.00, compared to ¥64,048,993.15 in the previous year, reflecting a decline of 29.8%[147]. - The cash outflow for debt repayment was ¥7,000,000.00, a decrease from ¥80,586,946.35 in the previous year, indicating a reduction in debt servicing[147]. Investments and Acquisitions - The company plans to acquire control of Guangzhou Delun Medical Investment Co., Ltd. through a cash payment, as approved in the board meetings held on May 27, 2021[5]. - The company holds a 7.39% stake in Fushun Bank, valued at 607,698,687.78 RMB, with a market value of 22,700,000 shares[52]. - The total profit from investment activities was ¥24,843,081.04, accounting for 257.43% of total profit, indicating a strong performance from the investment in Fushun Bank[43]. Operational Highlights - The company primarily engages in the research, production, and sales of permanent magnet switches and high/low voltage switchgear, along with software development and leasing of office space[27]. - The subsidiary Jilin Yongda Electric has established a marketing network covering over 20 provinces, providing comprehensive services including pre-sale, in-sale, and after-sale support[27]. - Yongda Electric has upgraded its products to meet the requirements of the national smart grid, enhancing features such as fault judgment, recording, and network interaction[27]. - The company has made breakthroughs in the electric furnace and chemical industries, focusing on project stability and success rates to drive overall performance growth[28]. Research and Development - Research and development expenses increased to ¥4,061,809.26, up from ¥3,825,219.23, indicating a focus on innovation[136]. - The company emphasizes a customer and market-driven approach in its R&D innovation system, ensuring continuous technological progress[33]. - The company has accumulated nearly 100 proprietary software products and has received multiple provincial and municipal technology advancement awards[33]. Corporate Governance and Compliance - The company has no significant environmental violations and complies with environmental protection regulations, with no penalties reported during the period[70]. - The integrity status of the company and its major shareholders is reported to be good during the reporting period[82]. - There were no related party transactions in daily operations during the reporting period[83]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 71,259[113]. - Guangzhou Huiyin Rifen Investment Partnership holds 23.81% of the shares, totaling 200,000,000 common shares[114]. - The second largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% with 32,263,200 common shares[115]. Financial Reporting and Standards - The semi-annual financial report has not been audited[126]. - The financial statements are prepared in RMB[127]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[174].
皓宸医疗(002622) - 2020 Q4 - 年度财报
2021-04-29 16:00
Financial Performance - The company reported a net loss attributable to shareholders of CNY 297,124,345.16 for the year[43]. - The company's operating revenue for 2020 was ¥114,345,046.98, a decrease of 26.38% compared to ¥155,321,874.62 in 2019[18]. - The net profit attributable to shareholders was -¥297,124,345.16, representing a decline of 4,093.11% from ¥7,440,930.97 in the previous year[18]. - The company reported a basic earnings per share of -¥0.3537, down from ¥0.0089 in 2019, marking a decline of 4,074.16%[18]. - The company reported a net profit after deducting non-recurring gains and losses of -¥328,122,627.47, compared to ¥3,235,682.04 in 2019, a decrease of 10,240.76%[18]. - The company reported a net profit decrease of 27.62% year-on-year, with a net profit margin of -0.88% for the year 2020[93]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2020, representing a year-over-year increase of 15%[195]. Shareholder Structure - The company’s major shareholder, Guangzhou Huiyin, holds 23.81% of the total shares, making it the largest shareholder[16]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership (Limited Partnership), holds 23.81% of the shares, totaling 200,000,000 shares[170]. - The second largest shareholder, Shaanxi International Trust Co., Ltd., holds 32,263,200 shares, representing a significant stake in the company[170]. - The company has a strategic relationship with its top shareholders, indicating potential alignment in future business strategies[170]. - The company has no controlling shareholder, and the actual controller is Jie Zhikuan, who has over 19 years of experience in the financial sector[175]. Business Operations - The company has not made any changes to its main business operations since its listing, continuing to focus on its core products[16]. - The company has undergone a change in actual control, with Beijing Shoutuo Ronghui becoming the actual controller after a partnership agreement with Guangzhou Huiyin[16]. - The company has maintained its existing business without launching new ventures during the reporting period, focusing on the leasing of various equipment and trade financing services[32]. - The company has established a strong customer base in traditional industries such as steel, chemicals, and coal, enhancing its market position[37]. - The company has transitioned its sales management model from a regional to an industry-based approach, focusing on clean energy and enhancing project stability through regular follow-ups[30]. Research and Development - The company is committed to continuous innovation in its traditional business of permanent magnet switches and software development, with a focus on expanding product categories and improving performance[43]. - The company has developed nearly 100 proprietary software products and has undertaken several major national and provincial scientific research projects[43]. - The company’s R&D investment in 2020 amounted to ¥7,996,687.44, a decrease of 13.52% compared to ¥9,247,013.41 in 2019[70]. - The company completed several R&D projects in 2020, including the development of the YDMC-100 permanent magnet circuit breaker and the ZN85 permanent magnet vacuum circuit breaker[64]. - The company aims to enhance its R&D capabilities and service capacity while expanding into new technologies, products, and markets[100]. Financial Management - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[5]. - The company has focused on cost management, improving internal controls, and optimizing asset structure to enhance operational efficiency[44]. - The company will strengthen its internal control system and risk management to adapt to the expanding market scale and business scope[104]. - The company has initiated the liquidation of underperforming subsidiaries to optimize its asset structure and reduce management costs[44]. - The company is committed to maintaining a strong leadership team to navigate market challenges and capitalize on new opportunities[190]. Market Strategy - The company plans to focus on the traditional permanent magnet switch industry while exploring collaborations with influential enterprises in target fields[101]. - The company aims to enhance product competitiveness and reduce production costs through the completion of R&D projects, thereby driving core competitiveness and business development[65]. - The company is expanding its market presence, targeting new regions with a planned investment of $50 million in marketing and infrastructure[156]. - The company plans to continue its focus on financial management and operational excellence to enhance shareholder value[188]. - The company aims to improve operational efficiency by implementing new management strategies, projected to reduce costs by 5%[195]. Corporate Governance - The company has appointed Zhonghua Certified Public Accountants as its auditor, with an audit fee of RMB 650,000 and a continuous service period of 15 years[124]. - The company has committed to reducing and regulating related party transactions to protect the interests of shareholders[113]. - The company will ensure that the interests of the listed company are not harmed by adhering to strict disclosure obligations regarding related party transactions[115]. - The company has a diverse board with members holding qualifications in law, finance, and management, which strengthens its governance structure[190]. - The company has seen a significant turnover in its board members, indicating a potential shift in strategic direction and governance[187]. Social Responsibility - The company actively participates in social responsibility initiatives, including environmental protection and employee rights[148]. - The company has implemented energy-saving measures and improved equipment to reduce energy consumption[148]. - The company contributed to pandemic relief efforts by donating during the COVID-19 outbreak[148]. - The company is committed to environmental sustainability, implementing new practices that reduce waste by 25%[161]. Regulatory Compliance - The company has faced regulatory scrutiny, resulting in a public reprimand from the Shenzhen Stock Exchange, but no financial penalties were imposed[196]. - There were no significant lawsuits or arbitration matters affecting the company during the reporting period, with total amounts involved in minor cases not reaching the disclosure threshold[125]. - The company did not experience any penalties or rectification issues during the reporting period[128].
皓宸医疗(002622) - 2021 Q1 - 季度财报
2021-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2021 was ¥16,635,191.36, representing a 93.80% increase compared to ¥8,583,632.58 in the same period last year[7] - The net profit attributable to shareholders was -¥3,191,400.03, a 134.08% increase in losses compared to -¥1,363,380.38 in the previous year[7] - The total comprehensive loss for Q1 2021 was CNY 7,329,294.08, compared to a comprehensive income of CNY 2,236,815.17 in the same quarter last year[46] - The net loss for Q1 2021 was CNY 3,191,400.03, compared to a net loss of CNY 1,363,380.38 in Q1 2020, reflecting a deterioration in performance[45] - Basic and diluted earnings per share for Q1 2021 were both CNY -0.0038, compared to CNY -0.0016 in Q1 2020[46] Cash Flow - The net cash flow from operating activities decreased by 33.71% to ¥4,069,851.03 from ¥6,139,924.33 year-on-year[7] - Operating cash inflows totaled 23,636,709.48 CNY, down 25.1% from 31,528,827.80 CNY in the previous period[53] - Cash outflows from operating activities amounted to 19,566,858.45 CNY, down 23.0% from 25,388,903.47 CNY in the previous period[53] - Cash received from other operating activities decreased by CNY 5,625,900, an 86.08% decrease compared to the same period last year, due to a prior year refund of CNY 5 million[16] - Cash received from tax refunds decreased by CNY 362,500, a 40.55% decrease compared to the same period last year, due to reduced VAT refunds[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,333,985,232.75, a decrease of 0.49% from ¥1,340,539,193.47 at the end of the previous year[7] - The company's current assets totaled CNY 313,201,982.18, down from CNY 322,139,458.28 at the end of 2020, indicating a decrease of about 2.9%[35] - The total liabilities of Rongyu Group as of March 31, 2021, were CNY 470,251,773.50, compared to CNY 469,476,440.14 at the end of 2020, showing a marginal increase of 0.2%[37] - The total liabilities as of the end of Q1 2021 amounted to CNY 623,249,356.51, slightly up from CNY 623,228,761.80 at the end of the previous quarter[41] - The total equity attributable to the owners of the parent company was CNY 863,733,985.29, down from CNY 871,063,279.37, indicating a decrease of approximately 0.8%[38] Investment and Income - Investment income decreased by 32.17% to ¥1,000,000, attributed to reduced net profits from the company's associate, Fushun Bank[15] - The company reported investment income of CNY 9,967,035.82 for Q1 2021, down from CNY 14,693,873.20 in the same period last year, a decrease of 32.5%[44] - The company experienced a credit impairment loss of CNY -268,749.08 in Q1 2021, compared to a gain of CNY 304,705.76 in the same period last year[44] Operating Costs and Revenue - The company's sales of switch products significantly boosted revenue, leading to an increase in operating costs by 148.75% to ¥1,077,000[15] - Total operating costs for Q1 2021 were CNY 30,562,144.94, up from CNY 26,174,755.76 in the previous year, indicating an increase of 16.5%[44] - The company reported a decrease in sales revenue from services, receiving 22,195,317.15 CNY compared to 24,099,037.56 CNY in the previous period[52] Shareholder Information - The company had a total of 45,224 common shareholders at the end of the reporting period[11] Other Financial Metrics - The weighted average return on net assets was -0.37%, a decrease of 0.27% compared to -0.10% in the previous year[7] - Research and development expenses for Q1 2021 were CNY 1,837,531.22, slightly down from CNY 1,896,486.46 in the previous year[44] - The company reported that frozen bank accounts totaled CNY 362,343,065.39, representing 0.020% of the latest audited net assets, with no significant impact on operations[19] Audit and Standards - The company has not undergone an audit for the first quarter report[59] - The company did not apply the new leasing standards for the first quarter[58]
皓宸医疗(002622) - 2020 Q3 - 季度财报
2020-10-30 16:00
Financial Performance - Operating revenue for the reporting period was CNY 28,585,157.25, a decrease of 3.25% year-on-year, while year-to-date revenue was CNY 58,217,553.26, down 40.09%[7] - Net profit attributable to shareholders of the listed company was CNY 4,708,167.83, an increase of 2,085.82% year-on-year, but year-to-date net profit was CNY -27,711,292.48, down 91.28%[7] - Basic earnings per share for the reporting period were CNY 0.0056, an increase of 1,766.67% year-on-year, while year-to-date earnings per share were CNY -0.0330, down 91.80%[7] - Total revenue for the period was CNY 58,217,553.26, a decrease of 40.17% compared to CNY 97,172,107.69 in the previous period[55] - Net profit for the period was CNY -27,711,292.48, compared to CNY -14,442,647.78 in the previous period, indicating a worsening loss[57] - The total comprehensive income for the period was CNY 4,166,131.84, compared to CNY -2,140,143.55 in the previous period[54] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,734,236,335.04, a decrease of 1.81% compared to the end of the previous year[7] - The total current assets decreased to CNY 427,014,637.15 from CNY 492,324,057.80, indicating a decline of about 13.3%[39] - The total liabilities decreased to CNY 477,195,110.53 from CNY 482,178,870.59, indicating a decline of approximately 1.6%[41] - The total owner's equity remained stable at ¥840,000,000.00, unchanged from the previous period[41] - The total liabilities amounted to CNY 482,178,870.59, with total equity at CNY 1,284,021,737.93, resulting in total assets of CNY 1,766,200,608.52[73] Cash Flow - Net cash flow from operating activities was CNY 20,328,615.23, an increase of 542.04% year-on-year, with year-to-date cash flow at CNY 32,107,785.48, up 289.33%[7] - The net cash flow from operating activities is 32,107,785.48, a significant improvement from -16,958,299.70 in the previous period[64] - The total operating cash inflow is 107,364,752.48, down from 130,760,093.67 in the previous period[64] - The total operating cash outflow is 75,256,967.00, compared to 147,718,393.37 in the previous period, indicating a reduction in cash outflows[64] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,900[11] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares, totaling 200,000,000 shares[11] Expenses and Income - The management expenses decreased by CNY 39.53 million, a 58.77% decrease compared to the same period last year, due to reduced expenses following the disposal of subsidiaries and enhanced cost control[17] - The tax expenses decreased by CNY 3.34 million, a 99.50% decrease compared to the same period last year, due to reduced income following the disposal of subsidiaries[18] - Financial expenses for the period were CNY 30,626,655.41, an increase from CNY 27,659,939.53 in the previous period[57] Investment and Other Income - Government subsidies recognized in the current period amounted to CNY 3,275,351.40, which are closely related to the company's business operations[8] - The company reported an investment income of CNY 12,835,346.84, up from CNY 11,320,331.56, showcasing improved returns on investments[48] - Investment income for the period was CNY 43,430,179.18, up from CNY 39,817,699.28 in the previous period[57] Changes in Equity - The total equity attributable to shareholders increased to CNY 1,149,486,049.34 from CNY 1,106,504,145.34, reflecting a positive shift in shareholder value[45] - The total owner's equity attributable to the parent company is CNY 1,284,022,263.97[73] Other Financial Metrics - The weighted average return on net assets was 0.38%, a slight increase of 0.36% compared to the previous year[7] - The company's long-term equity investments rose to ¥600,829,691.43 from ¥557,232,726.34, reflecting an increase of approximately 7.8%[40] - The company's cash and cash equivalents increased to ¥104,013,219.50 as of September 30, 2020, compared to ¥75,031,573.53 at the end of 2019, representing a growth of approximately 38.7%[39]
皓宸医疗(002622) - 2020 Q2 - 季度财报
2020-08-27 16:00
Financial Performance - The company's operating revenue for the first half of 2020 was ¥29,632,396.01, a decrease of 56.18% compared to ¥67,628,046.01 in the same period last year[17]. - The net profit attributable to shareholders was a loss of ¥32,419,460.31, representing a 120.50% increase in loss compared to a loss of ¥14,702,775.47 in the previous year[17]. - The total profit for the period was -¥32,383,605.73, with a net profit attributable to shareholders of -¥32,419,460.31[37]. - The basic and diluted earnings per share were both -¥0.0386, reflecting a 120.54% increase in loss per share compared to -¥0.0175 in the same period last year[17]. - The total comprehensive loss for the first half of 2020 was ¥28,851,587.81, compared to a loss of ¥12,136,722.72 in the first half of 2019, indicating a worsening of 137.5%[142]. - The net loss for the first half of 2020 was ¥32,419,460.31, compared to a net loss of ¥14,426,844.19 in the first half of 2019, representing a deterioration of 125.5%[141]. Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥11,779,170.25, a significant increase of 158.53% from a negative cash flow of ¥20,124,563.03 in the same period last year[17]. - The cash inflow from investment activities increased significantly to ¥64,048,993.15 in 2020, up from ¥22,501,787.75 in 2019, marking an increase of approximately 184%[150]. - The ending cash and cash equivalents balance increased to ¥83,901,505.05 in 2020 from ¥31,323,239.46 in 2019, reflecting a growth of approximately 168%[150]. - The company reported a credit impairment loss of ¥-35,177,451.37, which accounted for 108.63% of total profit[50]. - The company received tax refunds of ¥1,258,495.05 in 2020, down from ¥4,108,156.23 in 2019, indicating a decrease of approximately 69%[149]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,728,213,020.58, a decrease of 2.15% from ¥1,766,200,608.52 at the end of the previous year[17]. - The total liabilities at the end of the first half of 2020 were approximately 287.42 million, showing a decrease from the previous year[162]. - Current liabilities totaled CNY 390,513,063.25, down from CNY 469,547,128.97, indicating a reduction of about 16.83%[133]. - Non-current liabilities increased to CNY 90,744,609.25 from CNY 12,631,741.62, showing a significant rise of approximately 617.56%[133]. - The total owner's equity decreased to CNY 1,246,955,348.08 from CNY 1,284,021,737.93, representing a decline of about 2.89%[134]. Business Operations and Strategy - The company primarily engages in the research, production, and sales of permanent magnet switches and high/low voltage switchgear, as well as software development and services[25]. - The company has established a marketing network across over 20 provinces and cities in China, providing comprehensive pre-sale, in-sale, and after-sale services[25]. - The company emphasizes that future operational plans and targets do not constitute profit forecasts and are subject to market conditions[4]. - The company plans to focus on enhancing its capital structure and improving profitability in the upcoming periods[156]. - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive growth[161]. Subsidiaries and Investments - The company’s subsidiary, Zhiyong Technology, focuses on software products in four key areas: government big data, smart market supervision, smart IoT, and social credit services[26]. - The company’s subsidiary, Rongyu Huatuo, focuses on financing leasing and trade financing through accounts receivable management, maintaining existing business without expansion due to regulatory impacts[28]. - The company has initiated the liquidation of subsidiaries that have not generated substantial revenue, aiming to optimize asset structure and reduce management costs[39]. - The company reported a total investment of 400,096,775.18 RMB in financial assets, with a loss of 37,193,315.18 RMB during the reporting period[60]. Shareholder Information - The total number of shares remains at 840 million, with no changes in the shareholding structure reported[110]. - The total number of common shareholders at the end of the reporting period was 44,907[112]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 200,000,000 shares, representing 23.81% of total shares[113]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[73]. Regulatory and Compliance - The financial report for the first half of 2020 was not audited[129]. - The company has not engaged in any significant equity or non-equity investments during the reporting period[59][64]. - The company has not reported any violations regarding external guarantees[95]. - The company confirmed that any partial disposal of equity investments that does not result in loss of control will adjust capital reserves accordingly[188]. Risk Management - The company faces risks related to macroeconomic conditions and the long investment return period, which may affect expected returns[69]. - The company has assessed that its ability to continue as a going concern is good, with no significant doubts regarding its operational capability in the next 12 months[175]. - The company reported credit impairment losses of ¥35,177,451.37, a significant increase from ¥-107,410.75 in the previous year[141].
皓宸医疗(002622) - 2020 Q1 - 季度财报
2020-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2020 was ¥8,583,632.58, a decrease of 78.47% compared to ¥39,877,498.75 in the same period last year[7] - The net profit attributable to shareholders was -¥1,363,380.38, an improvement of 85.77% from -¥9,581,679.68 year-on-year[7] - The basic earnings per share were -¥0.0016, showing an improvement of 85.76% from -¥0.0114 in the same period last year[7] - Operating revenue for the period was ¥8,583,632.58, a decrease of 78.47% year-on-year, mainly due to the absence of advertising and consulting service income after the disposal of a subsidiary[14] - Operating costs decreased by 76.13% to ¥4,335,612.28, reflecting a reduction in business volume during the reporting period[14] - The net profit for Q1 2020 was a loss of CNY 1,363,380.38, compared to a loss of CNY 9,032,379.56 in the same period last year[41] - The net profit for the period was CNY 3,199,507.74, a significant improvement from a net loss of CNY 2,153,194.46 in the same period last year[45] Cash Flow - The net cash flow from operating activities was ¥6,139,924.33, a significant increase of 148.18% compared to -¥12,743,347.22 in the previous year[7] - The net cash flow from investing activities was -¥206,858.90, an increase of 98.38% compared to the previous year, due to significantly reduced external investment expenditures[14] - The net cash flow from financing activities was -¥12,386,312.15, an increase of 55.82% year-on-year, primarily due to higher bank loan repayments in the previous period[14] - The cash flow from operating activities generated a net cash inflow of CNY 6,139,924.33, compared to a net outflow of CNY 12,743,347.22 in the previous period[48] - Total cash inflow from operating activities was 13,413,075.11 yuan, while cash outflow was 14,014,258.86 yuan, resulting in a net cash outflow of 601,183.75 yuan[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,769,321,049.15, a slight increase of 0.18% from ¥1,766,200,608.52 at the end of the previous year[7] - The total current assets as of March 31, 2020, amounted to ¥481,646,691.36, a decrease from ¥492,324,057.80 as of December 31, 2019, reflecting a decline of approximately 2.4%[30] - The total liabilities as of March 31, 2020, were ¥483,062,496.05, slightly up from ¥482,178,870.59, indicating a marginal increase of about 0.2%[33] - The total assets of the company as of January 1, 2020, were 1,766,200,608.52 yuan, with total liabilities amounting to 482,178,870.59 yuan[54] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,602[10] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, held 23.81% of the shares, amounting to 200,000,000 shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11] Non-Recurring Items - The company recognized non-recurring gains and losses totaling ¥612,965.75, primarily from government subsidies and VAT refunds[8] Inventory and Receivables - The ending balance of accounts receivable decreased by 67.79% to ¥6,215,842.65 due to the maturity of notes and a decrease in new sales of switch products[14] - The ending balance of prepayments increased by 380.13% to ¥9,342,731.57, primarily due to increased material purchases during the reporting period[14] - Accounts receivable decreased to CNY 8,131,759.52 from CNY 10,640,874.92[36] - Inventory increased to ¥52,067,417.02 from ¥41,537,356.61, reflecting a growth of approximately 25.3%[31] Financial Management - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[18] - There were no derivative investments or violations regarding external guarantees during the reporting period, reflecting a conservative financial strategy[24][25] - The company reported no overdue amounts in its entrusted financial management activities, indicating effective management of financial risks[23] Changes in Control and Agreements - The company terminated share transfer agreements with Shanghai Chengyi and Anji Xingfeng, clarifying the end of negotiations regarding share transfers[15] - The actual controller of the company is expected to change following the completion of the equity changes involving Beijing Shoutuo Ronghui[16] Other Financial Information - The company executed new revenue and leasing standards starting in 2020, which may impact future financial reporting[58] - The first quarter report for 2020 was not audited, which may affect the reliability of the financial data presented[59]
皓宸医疗(002622) - 2019 Q4 - 年度财报
2020-04-29 16:00
Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2019, representing a year-on-year increase of 15%[11] - The net profit attributable to shareholders was 150 million RMB, which is a 10% increase compared to the previous year[11] - The company's operating revenue for 2019 was ¥155,321,874.62, a decrease of 63.23% compared to ¥422,405,637.01 in 2018[17] - The net profit attributable to shareholders for 2019 was ¥7,440,930.97, down 79.80% from ¥36,843,238.80 in 2018[17] - The company reported a basic earnings per share of ¥0.0089 for 2019, a decline of 77.75% from ¥0.040 in 2018[17] - The company reported a significant increase in cash flow from operating activities, indicating improved operational efficiency and financial health[17] - The net cash flow from operating activities increased by 437.96% to ¥22,750,889.82 in 2019, compared to ¥4,229,099.44 in 2018[17] - The company reported a total of ¥191,379,736.39 in restricted assets, primarily due to collateral for loans[77] - The company reported an investment income of ¥56,028,830.23, accounting for 441.75% of total profit, primarily from its stake in Fushun Bank[71] Business Strategy and Expansion - The company plans to expand its business into innovative technology and financial services, aiming for a 20% growth in these sectors over the next year[15] - The company aims to enhance its market presence through strategic partnerships and acquisitions, targeting a 30% increase in market share by 2021[15] - The company has established over ten subsidiaries, diversifying its operations into big data analysis and new retail sectors[15] - The company is focusing on R&D for new products in smart electrical equipment, with an investment of 100 million RMB allocated for this purpose in 2020[15] - The company aims to expand its product categories and enhance competitiveness through ongoing R&D efforts, which are expected to lower procurement costs[62] Risk Management and Compliance - The company has identified no significant risks that could adversely affect its production, financial status, or profitability[4] - The company is committed to strict risk management and scientific investment decisions to navigate macroeconomic and policy challenges[97] - The company has been publicly reprimanded by regulatory authorities for administrative violations, including environmental and safety issues[121] - The company received a public reprimand from the Shenzhen Stock Exchange for regulatory violations[186] Operational Efficiency and Cost Management - The company focused on cost management, leading to a reduction in expenses and improved operational efficiency across its three business segments[43] - In 2019, the total sales expenses decreased by 36.78% to ¥14,747,154.39 compared to ¥23,325,079.42 in 2018, primarily due to reduced expenditures and the exclusion of certain subsidiaries from the consolidation scope[58] - Management expenses fell by 51.35% to ¥77,035,558.96 in 2019 from ¥158,335,807.86 in 2018, attributed to decreased spending and the exclusion of specific subsidiaries post-equity transfer[58] Research and Development - The company has implemented a sales management model that combines regional and industry approaches, enhancing its presence in clean energy sectors[28] - The company completed several R&D projects in 2019, including the development of a 12KV-1250A high-voltage permanent magnet intelligent vacuum circuit breaker, which is aimed at enhancing product intelligence and digital capabilities[61] - The company’s innovative technology segment, Zhiyong Technology, has developed multiple products for various government agencies, including enterprise credit supervision systems and smart fire IoT platforms[38] - The number of R&D personnel increased to 109 in 2019, representing 24.83% of the total workforce, up from 13.29% in 2018[65] Shareholder and Governance Structure - The total number of shares outstanding is 840 million, with 839,976,750 shares being unrestricted[152] - The company does not have a controlling shareholder, as the largest shareholder does not have an actual controller[160] - The company’s actual controller is a domestic natural person, with no changes in the controlling shareholder during the reporting period[161] - The company has a comprehensive remuneration management system based on performance evaluation[187] Subsidiaries and Equity Transactions - The company completed the transfer of 100% equity of Zhongyuan Hengxin Industrial Group Co., Ltd. to Guoda Yongtai Investment Holding Group Co., Ltd. in April 2019[93] - The company announced the transfer of equity in its subsidiary Rongyu Interactive, reflecting strategic adjustments in its investment portfolio[147] - The company plans to complete the buyback of remaining shares of Shanghai Chen Shang by December 31, 2020, with a buyback price of RMB 46 million[92] Employee and Talent Management - The total number of employees is 439, with 205 in production, 83 in technical roles, 59 in sales, 20 in finance, and 72 in administration[190][191] - Employee education levels include 248 with vocational education or below, 96 with associate degrees, and 95 with bachelor's degrees or higher[191] - The company has implemented a compensation policy linking employee income to company performance, ensuring fairness across different departments and positions[192] Financial Reporting and Accounting Standards - The company will implement new accounting standards starting January 1, 2020, without retrospective adjustments affecting 2019 financial indicators[111] - The company plans to prepare consolidated financial statements according to the revised reporting format from 2019 onwards[110] - The company has not made any changes to accounting policies that would affect the financial statements for the reporting period[109] Social Responsibility - The company actively engaged in social responsibility initiatives, focusing on energy conservation, environmental protection, and safety management[139] - The company has implemented measures for the employment of disabled individuals and actively participates in social welfare activities[139]
皓宸医疗(002622) - 2019 Q3 - 季度财报
2019-10-30 16:00
Financial Performance - Operating revenue for the reporting period was CNY 29,544,061.68, down 74.64% year-on-year, and CNY 97,172,107.69 for the year-to-date, down 66.03% compared to the same period last year[7] - Net profit attributable to shareholders was CNY 215,395.72, a decrease of 98.78% year-on-year, with a year-to-date net loss of CNY 14,487,379.75, down 174.06%[7] - Basic and diluted earnings per share were CNY 0.0003, a decrease of 98.58% year-on-year, with a year-to-date loss per share of CNY -0.0172, down 173.82%[7] - The net profit for the period was a loss of CNY 14,442,647.78, compared to a profit of CNY 42,786,097.31 in the previous year[52] - The net profit for the third quarter of 2019 was CNY 16,084,445.30, compared to a net loss of CNY 19,540,657.06 in the same period last year, indicating a significant turnaround[56] Cash Flow - The net cash flow from operating activities was CNY 3,166,263.33, down 92.20% year-on-year, and CNY -16,958,299.70 for the year-to-date, down 148.16%[7] - The cash flow from operating activities showed a net outflow of CNY 16,958,299.70, contrasting with a net inflow of CNY 35,209,340.95 in the same quarter last year[61] - The net cash flow from operating activities decreased by 52.17 million RMB, reflecting a significant decline in sales collections compared to the previous year[17] - The cash inflow from investment activities was 190,100,572.92 CNY, while cash outflow was 214,565,733.11 CNY, leading to a net cash flow of -24,465,160.19 CNY[64] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,786,585,561.48, a decrease of 4.52% compared to the end of the previous year[7] - The total liabilities decreased from ¥526,918,994.40 to ¥496,827,393.54, representing a reduction of about 5.7%[36] - The company's cash and cash equivalents dropped significantly from ¥99,804,517.63 to ¥32,921,079.69, a decline of approximately 67%[33] - The total current liabilities were CNY 848,234,072.86, including short-term borrowings of CNY 130,000,000.00[74] Shareholder Information - The total number of shareholders at the end of the reporting period was 63,895, with the largest shareholder holding 23.81% of the shares[10] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, held 200,000,000 shares[12] Operational Metrics - The operating costs decreased by 76.66%, resulting in a reduction of 120.88 million RMB, in line with the decrease in operating revenue[17] - The total operating costs amounted to CNY 40,974,486.50, a decrease from CNY 130,501,883.28 year-over-year[43] - The total operating revenue for the first three quarters was CNY 97,172,107.69, a decrease of 66.0% compared to CNY 286,013,061.43 in the same period last year[50] Non-Operating Income and Expenses - Non-operating income included government subsidies of CNY 1,245,941.00, which are closely related to the company's business[8] - The company incurred tax expenses of CNY 3,360,879.35, compared to a tax benefit of CNY -9,013,316.06 in the previous year[52] Compliance and Governance - The company reported no non-compliance with external guarantees during the reporting period[25] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[26] - The company has not undergone an audit for the third quarter report[76] - The report indicates a significant focus on improving financial reporting and compliance with new regulations[76]
皓宸医疗(002622) - 2019 Q2 - 季度财报
2019-08-30 16:00
Financial Performance - The company's operating revenue for the first half of 2019 was ¥67,628,046.01, a decrease of 60.10% compared to ¥169,511,762.60 in the same period last year[17]. - The net profit attributable to shareholders was a loss of ¥14,702,775.47, representing a decline of 885.92% from a profit of ¥1,870,770.37 in the previous year[17]. - The net cash flow from operating activities was negative at ¥20,124,563.03, an increase in loss of 273.55% compared to a loss of ¥5,387,389.65 in the same period last year[18]. - Basic and diluted earnings per share were both -¥0.0175, a decrease of 895.45% from ¥0.0022 in the previous year[18]. - Total assets at the end of the reporting period were ¥1,787,776,330.93, down 4.46% from ¥1,871,234,376.91 at the end of the previous year[18]. - The net assets attributable to shareholders increased slightly by 0.74% to ¥1,289,951,672.02 from ¥1,280,529,058.29 at the end of the previous year[18]. - The company reported a total of ¥294,501.83 in non-recurring gains and losses during the reporting period[21]. - The company experienced a significant increase in non-recurring losses, with a 8,341.39% increase in net profit attributable to shareholders after deducting non-recurring gains and losses[17]. - The company achieved operating revenue of ¥67,628,046.01, a decrease of 60.10% compared to the same period last year, primarily due to macroeconomic impacts[39]. - The net profit attributable to shareholders was -¥14,702,775.47, reflecting a significant decline compared to the previous year[39]. Business Segments - The company operates in three main business segments: industrial, innovative technology, and financial services, aiming to integrate industry scenarios with big data technology and financial service platforms[24]. - The industrial segment focuses on the research, production, and sales of permanent magnet switches and high/low voltage switchgear, with a marketing network covering over 20 provinces[25]. - The innovative technology segment includes subsidiaries that provide data-driven digital marketing and advertising services, enhancing customer acquisition strategies[27]. - The financial services segment primarily involves trade financing through accounts receivable factoring, with a focus on credit risk assessment and management[29]. - The financial services segment is expanding its leasing business, particularly in transportation and equipment manufacturing sectors, with a focus on large private and state-owned enterprises[31]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has optimized its asset structure by liquidating subsidiaries that did not generate substantial revenue, improving overall operational efficiency[31]. - The company is committed to enhancing collaboration among its business segments to improve competitive advantages and operational synergies[31]. - The company is focusing on cost management and has implemented measures to enhance internal control, aiming for more efficient operations across its three business segments[40]. - The company aims to strengthen its market position by focusing on long-term customer relationships and expanding its client base in the industrial sector[26]. - The company is actively seeking to expand its customer base while maintaining stable existing customer resources in its industrial and innovative technology segments[35]. Investment and Financial Management - The company has increased its investment in Beijing Wantai Zhonglian Technology Co., Ltd. as part of its equity assets[32]. - The company has established a new private equity fund in collaboration with Shanghai Xianglan Asset Management Co., Ltd. to seize strategic investment opportunities[34]. - The company has made a total investment of 260,200,000 CNY in financial assets, with a fair value change of 10,920.00 CNY during the reporting period[62]. - The company reported a fair value loss of ¥49,200.00, representing 0.41% of total profit, attributed to the fair value changes of financial assets[52]. - The company has pledged assets worth ¥19,088.56 million as collateral for loans, with a loan amount of ¥130 million from Zhongrong International Trust Co., Ltd.[56]. Operational Challenges - The company faced public condemnation from regulatory authorities due to inaccurate information disclosed in a strategic cooperation agreement[84]. - The company reported a significant decrease in cash inflows from other operating activities, which fell to CNY 17,837,821.04 from CNY 109,766,204.45 in the previous year[145]. - The company’s total revenue from subsidiaries in the reporting period was significantly impacted by market competition and economic conditions[71]. - The company has not reported any new product launches or technological advancements during this period[160]. - The company has not experienced any significant environmental protection issues and is not classified as a key pollutant discharge unit by environmental authorities[101]. Governance and Compliance - The half-year financial report has not been audited[81]. - The company will enhance personnel training on relevant laws and regulations to improve operational standards and information disclosure quality[85]. - There were no major litigation or arbitration matters during the reporting period[83]. - The company has not engaged in any significant related party transactions during the reporting period[90]. - The company has not provided any guarantees to shareholders, actual controllers, or their related parties[98]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,116[115]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares, totaling 200,000,000 RMB common shares[115]. - The second-largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% of the shares, totaling 32,263,200 RMB common shares[115]. - The company reported a total external guarantee amount of 45,000,000 RMB, with an actual guarantee balance of 40,604,690 RMB, representing 31.48% of the company's net assets[98]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[117].